about
Validation of the MCL35 gene expression proliferation assay in randomized trials of the European Mantle Cell Lymphoma NetworkPreclinical development of CD37CAR T-cell therapy for treatment of B-cell lymphomaMinimal relapse risk and early normalization of survival for patients with Burkitt lymphoma treated with intensive immunochemotherapy: an international study of 264 real-world patientsPatient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphomaNo excess long-term mortality in stage I-IIA Hodgkin lymphoma patients treated with ABVD and limited field radiotherapyThe MCL35 gene expression proliferation assay predicts high-risk MCL patients in a Norwegian cohort of younger patients given intensive first line therapyTIGIT and PD-1 Mark Intratumoral T Cells with Reduced Effector Function in B-cell Non-Hodgkin LymphomaTisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma patients without measurable disease at infusionThe simplified follicular lymphoma PRIMA-prognostic index is useful in patients with first-line chemo-free rituximab-based therapy
P50
Q57169896-7C43FEAE-0ACB-4D4B-B8C2-661D4E3D527CQ64117924-7D7B7C82-15C2-434B-98B7-A5F376309952Q89524396-65919823-5AA7-43BB-AC3F-ABE0B71EE881Q89779304-6E1F9948-296D-41FE-BDDF-A5B121E4CD25Q90708594-0B7818DE-43A4-4A60-AE85-2C099635FD1AQ90771323-66671E8C-62B0-48A3-92DD-6F6DFCC80421Q91116760-107E1A14-DEA5-404C-BF0F-C54A79AE18ABQ92091223-ACFCFAF1-4FA6-4079-8902-5197DEB63834Q94914624-FC3B2A3D-6BFE-4702-B98C-D7357F03FEB4
P50
description
researcher
@en
name
Harald Holte
@en
type
label
Harald Holte
@en
prefLabel
Harald Holte
@en
P31
P496
0000-0001-9799-9428